Formulary
Enfuvirtide: Indications, Dosing, Side Effects and Interactions
Enfuvirtide inhibits the fusion of HIV to the host cell.
MedNext Academy | 3 min read
Enfuvirtide: Indications, Dosing, Side Effects and Interactions
Enfuvirtide inhibits the fusion of HIV to the host cell.
Drug action
Enfuvirtide inhibits the fusion of HIV to the host cell.
Indications and dose
**HIV infection in combination with other antiretroviral drugs**
- **Adult** (By Subcutaneous Injection): for resistant infection or for patients intolerant to other antiretroviral regimens 90 mg twice daily.
**HIV infection in combination with other antiretroviral drugs for resistant infection or for patients intolerant to other antiretroviral regimens for enfuvirtide**
- **Child 6-15 years** (By subcutaneous injection): 2 mg/kg twice daily (max. per dose 90 mg).
- **Child 16-17 years** (By subcutaneous injection): 90 mg twice daily.
Side effects
Common or very common Anxiety; appetite decreased; asthenia; concentration impaired; conjunctivitis; diabetes mellitus; gastrooesophageal reflux disease; haematuria; hypertriglyceridaemia; increased risk of infection; influenza like illness; irritability; lymphadenopathy; myalgia; nasal congestion; nephrolithiasis; nightmare; numbness; pancreatitis; peripheral neuropathy; skin papilloma; skin reactions; tremor; vertigo; weight decreased Frequency not known Diarrhoea; hypersensitivity; immune reconstitution inflammatory syndrome; nausea; osteonecrosis Side-effects, further information Hypersensitivity Hypersensitivity reactions including rash, fever, nausea, vomiting, chills, rigors, low blood pressure, respiratory distress, glomerulonephritis, and raised liver enzymes reported; discontinue immediately if any signs or symptoms of systemic hypersensitivity develop and do not rechallenge. Osteonecrosis Osteonecrosis has been reported in patients with advanced HIV disease or following long-term exposure to combination antiretroviral therapy.
Interactions
**Severe interactions:**
- ENTRY INHIBITORS Enfuvirtide Due to the metabolic pathway no clinically significant pharmacokinetic interactions are expected between enfuvirtide and nevirapine.
**Other interactions (2):**
- Enfuvirtide and Nevirapine can be co-administered without dose adjustments.
- Fusion Inhibitors Enfuvirtide 90 mg twice daily etravirine* AUC a C 0h a Enfuvirtide concentrations not studied and no effect is expected.
Pregnancy
Manufacturer advises use only if potential benefit outweighs risk.
Hepatic impairment
Manufacturer advises caution (no information available); increased risk of hepatic side effects in patients with chronic hepatitis B or C.
Medicinal forms
Medicinal forms No licensed medicines listed.
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Enfuvirtide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

